Press Releases

SQI Diagnostics Authorized to CE Mark its Automated SQiDworks™ Diagnostics Platform and QuantiSpot™ Rheumatoid Arthritis Assay

Released: Feb 11, 2009

Toronto, Canada, February 11th, 2009 – SQI Diagnostics Inc. (TSX-Venture: SQD), a medical systems automation company focused on evolving laboratory-based biomarker testing, today announced that it is authorized to use the CE Mark on the Company's automated SQiDworksTM Diagnostics Platform. The Company is also authorized to use the CE Mark for its QuantiSpot™ Rheumatoid Arthritis (RA) Assay, the first kit in a menu of microarray consumable tests being developed for the SQiDworks platform. This regulatory milestone allows SQI to market its automated platform and QuantiSpot RA test to diagnostic laboratories in the European Union.

"The ability to CE mark these products shows that we have met the requisite health, safety and environmental protection requirements covering these medical devices in the EU and is further validation that our technology is ready for commercialization," said Claude Ricks, CEO and President of SQI Diagnostics. "As in North America, European laboratories are seeking automated solutions to respond to the growing demand for biomarker testing. While the potential market for our platform in Europe is significant, our near-term objective remains obtaining FDA clearance to market our platform and tests in the U.S., and to initially focus our commercialization efforts in North America."

The SQiDworks automated platform is a significant advancement from the current industry standard methods for biomarker testing, which can be inefficient and labour intensive. The platform is used to analyze multiple-biomarkers in a fully automated 'load-and-go' process. The platform incorporates the Company's proprietary IgX-Plex™ technology to allow multiplexed quantification of target antibody sub-classes (IgA, IgG, IgM) for multiple biomarkers. The lead test for the platform is the QuantiSpot RA assay, which provides simultaneous analysis of four biomarkers commonly tested and used to aid in the diagnosis and monitoring of rheumatoid arthritis, including the anti-CCP-IgG marker that has been adopted rapidly over the last five years.

About SQiDworks
The SQiDworks Diagnostics Platform is a fully-automated fluidics workstation, scanner and analytical device used to process SQI Diagnostics proprietary QuantiSpot microarray test devices. The platform fully integrates all assay steps for hands-free work-flow and is compatible with standard lab automation systems. The platform is capable of processing up to 240 patient samples per run, and, when combined with the Company's QuantiSpot multiplexed tests, can produce quantified determinations for up to 960 individual test results per hour resulting in significant laboratory efficiencies and cost-savings.

About QuantiSpot
The SQI Diagnostics microarray device, QuantiSpot, is a multiplexed assay consumable for use with the SQiDworks workstation. QuantiSpot tests are currently being developed for the detection and quantification of biomarkers used in the diagnosis of Autoimmune Disease, Infectious Disease and Allergic conditions, among others. Each of the 96 wells of the QuantiSpot device contains proprietary microarrays for duplicate antibody capture, in-sample calibration and redundant test controls. When combined with the SQiDworks fully-automated workstation, users are able to process multiplexed assays to quantify serum concentrations of up to 12 individual biomarkers or the qualitative detection of up to 24 biomarkers per patient.

About SQI Diagnostics
SQI Diagnostics is a medical systems company that develops proprietary technology in multiplexing, miniaturization and automation. SQI provides laboratories the ability to simultaneously analyze multiple biomarkers, deliver accurate and quantitative patient results in less time, significantly reduce labor, and increase profits...All in One Drop. Please visit www.sqidiagnostics.com.

About Mount Sinai Services
Mount Sinai Services, Inc. (MSS) is the commercial arm of the Pathology and Laboratory Medicine Department at Mount Sinai Hospital in Toronto, Canada. MSS provides extensive custom laboratory services for researchers, pharmaceutical companies and other industry partners. These services include: project management, consultation for clinical trials, pathology, scientific/research projects, screening programs such as antenatal lab services, infectious disease, drug development and evaluation for safety and pharmacokinetics, genetic and molecular diagnostics, as well as, research & development for diagnostic assays for new platforms or for medical devices. Mount Sinai Services through its exclusive relationship with Mount Sinai Hospital, complies with Canada's Good Laboratory Practice (GLP) standard, is audited by the FDA and is accredited by the College of American Pathologists. For additional information please visit www.mountsinaiservices.com.

For further information please contact:

Chief Financial Officer
Andrew Morris
416.674.9500 ext. 229
amorris@sqidiagnostics.com

Investor Relations
James Smith
416.815.0700 ext. 229
jsmith@equicomgroup.com

Certain information in this press release is based on beliefs and assumptions of the Company's senior management and information currently available to it that may constitute forward-looking information within the meaning of securities laws. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements.

This release was prepared by management of the Company who takes full responsibility for its contents. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release.